Difficulty: Medium
Average Score: 91%
Practice
A patient receiving transurethral alprostadil asks about intracavernous administration. Which information would be included in the explanation?
Correct answer
A
Rationale
Transurethral alprostadil has fewer side effects (e.g., less priapism or fibrosis) compared to intracavernous injections, though both increase penile arterial flow. Intracavernous doses are lower (5-40 mcg vs. 125-1000 mcg transurethrally), and volume isn├óÔé¼Ôäót 0.1 mL, making option A the key distinction to explain.